Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nordic Certican Trial in Heart and Lung Transplantation (NOCTET)
2005-002060-28Phase 4Completed
- Sponsor
- Novartis
- Start
- Jul 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of everolimus in post-orthotopic heart transplantation status and chronic kidney disease (CKD) (2 arms), sponsored by Novartis. Primary endpoint: Change in measured glomerular filtration rate (mGFR) from baseline to Month 12. Started Jul 2005; status: completed.
02
Drugs
everolimus
03
Conditions
post-orthotopic heart transplantation statuschronic kidney disease (CKD)
Beyond the preview
Go deeper on 2005-002060-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002060-28.